.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Citi
Cipla
Medtronic
Merck
US Army
Baxter
UBS
Covington

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,579,981

« Back to Dashboard

Which drugs does patent 6,579,981 protect, and when does it expire?


Patent 6,579,981 protects DENAVIR and is included in one NDA.

This patent has seventy-one patent family members in twenty-seven countries.

Summary for Patent: 6,579,981

Title: Antiviral guanine derivatives
Abstract:A compound of formula (I) ##STR1## or a salt or acyl derivative thereof, in which X represents chlorine, C.sub.1-6 alkoxy, phenoxy, phenyl C.sub.1-6 alkoxy, NH.sub.2, --OH or --SH, is useful in treating viral infections.
Inventor(s): Jarvest; Richard Lewis (Surbiton, GB), Harnden; Michael Raymond (Horsham, GB)
Assignee: Novartis International Pharmaceutical Ltd. (Hamilton, BM)
Application Number:08/311,291
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Mylan Pharms IncDENAVIRpenciclovirCREAM;TOPICAL020629-001Sep 24, 1996RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,579,981

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8325271Sep 21, 1908
United Kingdom8322199Aug 18, 1983
United Kingdom8408322Mar 30, 1984

Non-Orange Book Patents for Patent: 6,579,981

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,388,074 Process for the preparation of purine derivatives► Subscribe
5,075,445 Guanine derivatives► Subscribe
6,573,378 Antiviral guanine derivatives► Subscribe
6,187,922 Process for the preparation of purine derivatives► Subscribe
5,684,153 Process for the preparation of purine derivatives► Subscribe
5,886,215 2-acetoxymethyl-4-halo-butyl-1-yl acetates► Subscribe
5,250,688 Purine derivatives► Subscribe
5,246,937 Purine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,579,981

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain543213► Subscribe
European Patent Office0182024► SubscribeSPC/GB94/002United Kingdom► Subscribe
Spain535283► Subscribe
Spain8602791► Subscribe
Denmark8504246► Subscribe
Denmark424685► Subscribe
Denmark167019► Subscribe
Cyprus1746► Subscribe
United Kingdom8322199► Subscribe
Finland87564► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
UBS
Farmers Insurance
Fish and Richardson
Deloitte
Moodys
Daiichi Sankyo
Accenture
Fuji
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot